tetano
Editor, Senior Moderator
Gene Ther. 2015 Apr 2. doi: 10.1038/gt.2015.31. [Epub ahead of print]
[h=1]Adenovirus-mediated artificial microRNAs targeting matrix or nucleoprotein genes protect mice against lethal influenza virus challenge.[/h] Zhang H[SUP]1[/SUP], Tang X[SUP]1[/SUP], Zhu C[SUP]1[/SUP], Song Y[SUP]1[/SUP], Yin J[SUP]1[/SUP], Xu J[SUP]2[/SUP], Ertl HC[SUP]3[/SUP], Zhou D[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus (IV) infection is a major public health problem, causing millions of cases of severe illness and as many as 500,000 deaths each year worldwide. Given the limitations of current prevention or treatment of acute influenza, novel therapies are needed. RNA interference (RNAi) through microRNAs is an emerging technology that can suppress virus replication in vitro and in vivo. Here, we describe a novel strategy for treatment of infuenza based on RNAi delivered by a replication-defective adenovirus (Ad) vector, derived from chimpanzee serotype 68 (AdC68). Our results showed that artificial microRNAs (amiRNAs) specifically targeting conserved regions of the IV genome could effectively inhibit virus replication in HEK293 cells. Moreover, our results demonstrated that prophylactic treatment with AdC68 expressing amiRNAs directed against M1, M2 or NP genes of influenza virus completely protected mice from homologous A/PR8 virus challenge and partially protected the mice from heterologous influenza A virus strains such as H9N2 and H5N1. Collectively, our data demonstrate that amiRNAs targeting the conserved regions of influenza A virus delivered by Ad vectors should be pursued as a novel strategy for prophylaxis of influenza virus infection in humans and animals.Gene Therapy accepted article preview online, 02 April 2015. doi:10.1038/gt.2015.31.
PMID: 25835311 [PubMed - as supplied by publisher]
[h=1]Adenovirus-mediated artificial microRNAs targeting matrix or nucleoprotein genes protect mice against lethal influenza virus challenge.[/h] Zhang H[SUP]1[/SUP], Tang X[SUP]1[/SUP], Zhu C[SUP]1[/SUP], Song Y[SUP]1[/SUP], Yin J[SUP]1[/SUP], Xu J[SUP]2[/SUP], Ertl HC[SUP]3[/SUP], Zhou D[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus (IV) infection is a major public health problem, causing millions of cases of severe illness and as many as 500,000 deaths each year worldwide. Given the limitations of current prevention or treatment of acute influenza, novel therapies are needed. RNA interference (RNAi) through microRNAs is an emerging technology that can suppress virus replication in vitro and in vivo. Here, we describe a novel strategy for treatment of infuenza based on RNAi delivered by a replication-defective adenovirus (Ad) vector, derived from chimpanzee serotype 68 (AdC68). Our results showed that artificial microRNAs (amiRNAs) specifically targeting conserved regions of the IV genome could effectively inhibit virus replication in HEK293 cells. Moreover, our results demonstrated that prophylactic treatment with AdC68 expressing amiRNAs directed against M1, M2 or NP genes of influenza virus completely protected mice from homologous A/PR8 virus challenge and partially protected the mice from heterologous influenza A virus strains such as H9N2 and H5N1. Collectively, our data demonstrate that amiRNAs targeting the conserved regions of influenza A virus delivered by Ad vectors should be pursued as a novel strategy for prophylaxis of influenza virus infection in humans and animals.Gene Therapy accepted article preview online, 02 April 2015. doi:10.1038/gt.2015.31.
PMID: 25835311 [PubMed - as supplied by publisher]